Dopamine D1 receptor agonists as antiparkinson drugs

By Mailman R.B.   Nichols D.E.  

Trends in Pharmacological Sciences, Vol. 19, Iss. 7, 1998-07 ,pp. : 255-256

Elsevier

Access to resources Recommend Favorite

Relative efficacies of -opioid receptor agonists at the cloned human -opioid receptor

By Quock R.M.   Hosohata Y.   Knapp R.J.   Burkey T.H.   Hosohata K.   Zhang X.   Rice K.C.   Nagase H.   Hruby V.J.   Porreca F.   Roeske W.R.   Yamamura H.I.  

European Journal of Pharmacology, Vol. 326, Iss. 1, 1997-05 ,pp. : 101-104

Elsevier

Access to resources Recommend Favorite

The Opioid Receptor Independent Actions of Kappa Receptor Agonists in the Cardiovascular System

By  

Current Pharmaceutical Design, Vol. 10, Iss. 20, 2004-08 ,pp. : 2429-2444

Bentham Science Publishers

Access to resources Recommend Favorite

Differential antagonism of the rate-decreasing effects of -opioid receptor agonists by naltrexone and norbinaltorphimine

By Powell K.R.   Holtzman S.G.  

European Journal of Pharmacology, Vol. 377, Iss. 1, 1999-07 ,pp. : 21-28

Elsevier

Access to resources Recommend Favorite

Effects of -opioid receptor agonists on long-term cocaine use and dopamine neurotransmission

By Collins S.L.   D'Addario C.   Izenwasser S.  

European Journal of Pharmacology, Vol. 426, Iss. 1, 2001-08 ,pp. : 25-34

Elsevier

Access to resources Recommend Favorite